Please login to the form below

Not currently logged in
Email:
Password:

Webinar: AMNOG – One Year On

IMS Consulting Group and Booz & Co will discuss the changes to Germany’s pharma pricing system in the latest PMLiVE webinar on Monday 23 April

Germany Rhine

Once the first country in Europe to get innovative products, thanks to its favourable pricing structure, Germany used to be a popular launch destination for the pharmaceutical industry.

In December AstraZeneca's antiplatelet drug Brilique (ticagrelor) become the first drug to be backed under the country's new pricing assessment laws, but the introduction of AMNOG and the G-BA test has left many in pharma wondering if they would not be better off avoiding the country altogether.

On Monday 23 April at 12:30pm (UK time) PMLiVE's latest webinar, AMNOG - One Year, will feature speakers from IMS Consulting Group and Booz & Co discussing these important pricing changes and what they mean for pharma. To registor for the free webinar use the box below or click this link.

 

The webinar can be viewed on this page on Monday and then shortly after it finishes it will be available here in an archived form.

• PMLiVE's country report series also has more on the German healthcare market

20th April 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Red Health

Red Health was formed in 2007 to bring something fresh to the healthcare PR world. Our approach was simple –...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics